Mutant K-ras provides an independent negative predictive marker for epidermal growth factor receptor (EGFR)-targeted therapy in colorectal cancers (CRCs). Rapid, sensitive, and cost-effective screening for K-ras status will overarch rational personalized medicine. Stool-based DNA testing offers unique advantages for CRC screening such as noninvasiveness, high specificity, and patient compliance, whereas complicated procedures and the low sensitivity of the present approaches have hampered its application on a wide scale. In this study, a chip-based temperature gradient capillary electrophoresis (TGCE) technique was applied to detect low-abundance K-ras mutations under a pooled experiment and analyze K-ras mutations in 30 paired stool samples and cancer tissues of CRC patients and 15 stool samples of healthy volunteers. The chip-based TGCE results showed that the successful analysis of K-ras status could be achieved within 6 min with an extremely low sample consumption of 14 nl. Detection is sensitive enough to reliably report 0.2% mutant CRC cells in a wild-type background, and 0.5 ng of template DNA was sufficient for chip-based TGCE. Of the 30 stool samples of CRC patients analyzed, 17 (57%) harbored K-ras mutations, and the lowest percentage of the detectable mutant K-ras in stool samples was 2%. The coincidence rate for K-ras mutations between stools and tissues obtained by the chip-based method reached 97% (29/30). One of the 15 stool samples of normal controls carried K-ras mutations, producing a specificity of 93%. Clone sequencing data entirely confirmed the results obtained by chip-based TGCE. The study demonstrates that chip-based TGCE is capable of rapidly screening low-abundance K-ras mutations with high sensitivity, reproducibility, simplicity, and significant savings of time and sample. Application of this method to genotype the K-ras gene in stools would provide a potential means for predicting the effectiveness of EGFR-targeted therapy in CRC patients using noninvasive approaches.
Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that controls cell growth, differentiation, and transformation, and is highly expressed in most common human cancers. It has been reported that EGFR expression is detected in up to 80% of colorectal cancer (CRC) patients and is associated with metastasis and reduced survival rates. 1 Therefore, several therapeutic agents that target EGFR, such as cetuximab and panitumumab, were developed for CRC treatment and significantly improved the survival rate and living quality of patients. 2, 3 The K-ras gene-encoded 21-kD protein, a key downstream effector of EGFR, has a critical role in controlling signal transduction pathways during cell growth. Constitutively activating mutations in K-ras, particularly at 'limited hot spot' codons 12 and 13, may lead to uncontrolled cell proliferation and may render tumor cells independent of EGFR signaling and thereby resistant to EGFR-targeted therapies. [4] [5] [6] An American Society of Clinical Oncology (ASCO) provisional clinical opinion (PCO) has addressed the utility of K-ras gene mutation testing in patients with metastatic CRC to predict the response to anti-EGFR therapy with cetuximab or panitumumab. 7 Therefore, it is of the utmost importance to screen and assess these patients for K-ras status to guide personalized medicine and to avoid the application of costly drugs that would only cause toxic side effects.
In the present screening strategies, stool-based DNA testing for CRC may offer unique advantages over other kinds of clinical materials such as cancer tissues because of noninvasiveness, high specificity, and patient compliance. [8] [9] [10] However, the proportion of genes derived from cancer cells in stools is as low as 1%. 11 At this concentration, mutations in stool DNA will not be readily detected using the most currently available gene analyzing methods, 12 such as restriction fragment length polymorphism (RFLP), 13 single-strand conformation polymorphism (SSCP), 14 and microarray chips. 15 The major drawbacks of these assays are that they lack sufficient sensitivity and high stability, and they are rather time and sample consuming and expensive for use in screening for molecular diagnostic purposes. Therefore, a rapid, sensitive, and economical method for clinical detection of K-ras genotypes in stools is in great demand. In recent years, most of the slab gel-based techniques for the detection of nucleotide mutations have been developed and implemented in capillary electrophoresis (CE) systems, with significant improvements in sensitivity and detection speed. 16 Temperature gradient capillary electrophoresis (TGCE) is a mutation screening technology that was developed by transplanting temperature gradient gel electrophoresis (TGGE) to a CE platform, in which DNA fragments consisting of homoduplexes and heteroduplexes are separated according to the different melting temperatures (Tm). 17 During electrophoretic separation, the sharply retarded mobility of heteroduplexes facilitates the achievement of highresolution efficiency for even a single nucleotide change. It is superior to many of the previously listed CE-based presequencing screening techniques. Another outstanding advantage of TGCE is its ability to analyze a wide variety of mutations without knowing their exact nature beforehand, which allows the detection of all base changes in the target DNA fragments. 16, 18, 19 As for the K-ras gene studied here, both codons 12 and 13 that contribute to directing chemotherapy can also be detected simultaneously.
Conventional TGCE requires at least 10% of the mutant DNA in a wild-type DNA background, but it is not sufficiently sensitive for the detection of K-ras mutations in cancer cells within stool samples. 20 The efficiency of detecting genetic variants can be much improved when the electrophoretic process is transplanted onto the microfluidic chip, a new microanalysis system with notable advantages involving higher sensitivity, increased speed, and reduced sample/reagent consumption. 21, 22 Buch et al 23 first fabricated a microfluidic device, employing TGCE to rapidly achieve the successful detection of model single-nucleotide polymorphism (SNP) samples. However, the large external heater assemblies in their spatial format increased difficulty with respect to accuracy control and miniaturization. 23 In our previous work, a chip-based CE platform integrated with a slantwise radiative heating system that was able to establish spatial temperature gradient using simple peripheral equipment and manipulation was developed for very simple, reliable, and cost-effective DNA mutation detection by chipbased TGCE. Various SNP samples and K-ras gene mutations in six colon cancer cell lines were successfully detected rapidly within 6 min. 24 In the present study, we further explore the possibility of chip-based TGCE analysis for the detection of low-abundance K-ras mutations and the feasibility for genotyping the K-ras gene in DNA extracted from stools to perform screening and predict the effectiveness of EGFRtargeted therapy in patients with CRC.
MATERIALS AND METHODS Cell Lines and Clinical Samples
Human CRC cell lines SW480 and HT29 were cultivated at 37 1C with 5% CO 2 in DMEM culture medium supplemented with 10% fetal bovine serum. A total of 30 naturally evacuated stool samples from CRC patients were collected on the defecation day 42 weeks after colonoscopy and biopsy. The stool sample of each patient was aliquoted into several equal units of B150 mg. Aliquots were placed in the 2 ml freezing tube and then immersed in liquid nitrogen. In addition, 30 paired primary CRC tissues were stored in a À80 1C freezer until analyzed. The study complied with approved institutional guidelines regarding patient information and consent. None of the patients underwent preoperative radiotherapy and chemotherapy, and all gave informed consent for our study. The characteristics of the patients are summarized in Table 1 . The median age of the patients was 58 years (range 32-74 years). There were 19 male and 11 female patients. The tumors were located in the colons in 17 patients and in the recta in 13 patients. The clinical stage of the patients according to Dukes' classification was as follows: stage A in 6 patients, stage B in 4 patients, stage C in 9 patients, and stage D in 11 patients. As a normal control, 15 stool samples were obtained from healthy volunteers who had no evidence of malignant tumors on colonoscopy, gastroduodenoscopy, and upper abdominal ultrasonography. As shown in Table 1 , the median age of the healthy volunteers was 56 years (range 45-75 years). There were 9 males and 6 females.
DNA Extraction and PCR Amplification
Genomic DNA was extracted from cell lines and frozen CRC tissues using a QIAamp DNA mini kit, and genomic DNA from the paired stool samples was isolated using a QIAamp DNA Stool mini kit. To detect K-ras point mutations at codons 12 and 13 (exon 1), a 293-bp fragment was amplified by PCR using the following primers: 5 0 -GTACTGGTGGAG TATTTGATAGTG-3 0 (forward) and 5 0 -AAAGAATGGTC CTGCACCAGTAATA-3 0 (reverse). The forward primer was synthesized with a 40-bp GC-rich region at the 5 0 end to artificially introduce a GC-clamp (5 0 -CGCCCGCCGCGCCC CGCGCCCGTCCCGCCGCCCCCGCCCG-3 0 ). 17 PCR amplification was performed in 25 ml reaction mixture containing 
Instrument Fabrication
A crossed-channel glass chip with a 1.0-cm-long sample loading channel and a 4.5-cm separation channel from the crossing to the outlet reservoir (5.0 cm total length) were fabricated by wet etching and thermal bonding as described in Jia et al. 25 A laboratory-assembled chip-based CE system with a confocal laser-induced fluorescence (LIF) detection device described elsewhere and equipped with a 473-nm diode laser as an excitation source was used in this work. 26 A home-built four-output 1500 V programmable power supply was used for on-chip sample injection and electrophoretic separation. The fluorescence signal was recorded by a chart recorder. The slantwise radiative heating system-based TGCE system in the microfluidic chip was set up for DNA mutation analysis as shown in Figure 1 . A homemade thermostated heater plate consisting of an aluminum plate and a semiconductor heating element was slightly slanted relative to the plane of the glass chip by inserting a thin spacer between the plate and chip at the upstream end of the separation channel.
The temperature was raised to a set temperature by a computer program written in LabVIEW 6.0. A Pt100 sensor chip epoxyed to the top of the aluminum plate maintained the set temperature by feedback-controlling the heating voltage. Owing to differences in radiative heating along the 3-cm length of the heating region, a continuous and uniform spatial temperature gradient formed.
Analysis for Mutation by Chip-Based TGCE GC-clamped PCR amplicons from cell lines and clinical samples were denatured and reannealed to form heteroduplexes. Crude PCR products were used without further purification. The denaturing and reannealing procedure is as follows: the temperature was held for 3 min at 95 1C, ramped from 95 to 25 1C at a rate of 2 1C per min, held for 3 min at 25 1C, and finally ramped from 25 to 4 1C. The microchannels were rinsed with 0.2 M HCl and water and then filled with sieving matrix, 3% of PVP dissolved in 1 Â TBE buffer with 1 mM YOYO-1. A total of 25 ml of sieving matrix solution was added to the buffer reservoir (BR), the sample waste reservoir (SW), and the buffer waste reservoir (BW). The crude PCR product (25 ml) diluted in water (1:50) was added to the sample reservoir (SR). The heater plate was mounted on the chip at a 0.41 slanting angle as described before 24 and thermostated at 73 1C to create a 5 1C temperature gradient from 55 to 60 1C along the separation channel. During the loading stage, the DNA sample was electrokinetically introduced into the channel by applying the following voltages to the four reservoirs for 80 s: BR, þ 200 V; SR, 0 V; SW, þ 400 V; and BW, þ 300 V; and during the separation stage: BR, 0 V; SR, þ 50 V; SW, þ 50 V; and BW, þ 250 V. Chip-based TGCE assays were performed blindly to detect K-ras mutations in paired stool samples and cancer tissues from these CRC patients and in stool samples from age-and sex-matched controls.
Sensitivity of the Chip-Based TGCE Cell lines HT29 and SW480, harboring wild-type K-ras and a homozygous GTT mutant at codon 12, 27 were separately Tumor site
Colon 17
Rectum 13 Figure 1 Schematic view of chip-based TGCE system. SR: sample reservoir; BR: buffer reservoir; SW: sample waste reservoir; BW: buffer waste reservoir.
Chip-based detection of stool K-ras mutation H Zhang et al cultivated to logarithmic phase. After digestion with trypsin into single-cell suspensions, SW480 cells were pooled at ratios of 1:1, 1:4, 1:16, 1:64, 1:128, 1:256, and 1:512 to realistically simulate tumor heterogeneity. Genomic DNA extraction and amplification of the 293-bp fragments were performed to create target samples for chip-based TGCE. To determine the minimal amount of DNA required for reliable mutation detection, the genomic DNA of 1:1 mixed HT29 and SW480 cells was diluted 250-, 300-, 350-, 400-, 450-, and 500-fold to simulate low-concentration samples. PCR products amplified from these diluted templates were directly analyzed.
DNA Direct Sequencing and Clone Sequencing Analysis
All PCR amplicons of the K-ras gene were purified using the DNA purification kit and directly sequenced to confirm the status of codons 12 and 13 using an ABI 377 sequencer. TA clone sequencing was adopted for the samples that showed mutation peak profiles in the electropherograms of chipbased TGCE that were not detectible by direct sequencing.
Analysis of Reproducibility
To show the reproducibility and robustness of the chip-based TGCE approach, the 50-fold diluted crude PCR product of the stool sample of patient no. 9 was continuously run in replicates for four separation cycles to show the intra-assay variation. The interassay variation was analyzed from four samplings from PCR products of the stool sample of patient no. 9 on four separate TGCE detections in which the sieving matrix was refilled and the temperature gradient was re-formed.
Statistical Analysis
All statistical analyses employed Fisher's exact test to compare proportions. A two-tailed P-value of o0.05 was considered statistically significant.
RESULTS

Melting Calculations for the K-ras Gene Region
Based on the melting predictions, DNA fragments carrying mutations in high-melting domains will not be separated by TGCE because of loss of sequence-dependent migration upon complete strand separation. This problem can be overcome through the introduction of a GC-clamp at one end of the fragment to convert the fragment to a single low-melting domain, ensuring that any mutation present in the target fragment is detectable. 16 In this study, the Melt 94 program was used to establish the melting map of the 253-bp K-ras gene region (Figure 2 ). The melting map indicates that codons 12 and 13 ( þ 129 bp to þ 134 bp) lie in the highmelting domain with a Tm of E77 1C. The same type of calculation performed for the fragment containing a 40-bp GC-clamp at its 5 0 end predicts that the fragment has an additional high-melting domain with a Tm of 95 1C at its 5 0 end, which allows the detection of mutations at codons 12 and 13.
Sensitivity of Chip-Based TGCE Under the spatial temperature gradient, a single assay time of 6 min was realized with an extremely low sample consumption of 14 nl. Samples with heterozygous mutations will resolve into multiple peaks on the electropherogram that correspond to heteroduplexes and homoduplexes. As shown in Figure 3a , TGCE could identify mutant K-ras with an analytical sensitivity as low as 0.2% (1:512) when the method was applied to a dilution series of SW480 cells exhibiting homozygous 2G-T mutations in a wild-type HT29 cell background. In comparison, PCR product sequencing required that at least 20% of the mutant cells be in the wildtype background (Figure 3b ). As shown in Figure 4 , we found that multi-peaks were clearly resolved for all PCR products amplified from a series of diluted template and that 1 ml of 500-fold diluted initial template DNA (a total of 0.5 ng) was sufficient for chip-based TGCE analysis.
Detection of Mutant K-ras in Clinical Samples
In this study, 30 paired stool samples and cancer tissues from CRC patients were analyzed using chip-based TGCE and sequencing (Tables 2 and 3 ). The chip-based TGCE showed that 17 (57%) of the 30 stool samples analyzed contained K-ras mutations that were present in 16 (53%) of the corresponding cancer tissues, whereas the direct sequencing only revealed mutations in 6 stools (20%) and 10 tissues (33%). The former method has a much higher detection rate for the K-ras mutation in the stools (Po0.05). Chip-based TGCE disclosed that 1 of the 15 healthy volunteers contained K-ras mutations, whereas direct sequencing disclosed none, producing a specificity of 93 and 100%, respectively. No significant difference was noted in the specificities of the two methods (Table 3) . Clone sequencing confirmed all positive results of TGCE assay for the patients and volunteers with Chip-based detection of stool K-ras mutation H Zhang et al mutant K-ras under the sensitivity of direct sequencing. For the CRC patients, K-ras mutations at both codons 12 and 13 were detected. Besides the hot spots, mutations at codon 10 in the stool sample and cancer tissue of patient no. 21 were also revealed ( Figure 5 ). Six representative samples with lowabundance K-ras mutations are shown in Figure 5 . The lowest mutation proportion was 2% and occurred in stool sample of patient no. 14 (1/50 clones). For the healthy volunteers, Control-4 who gave a mutant electrophoresis pattern carried a C/T mutation at codon 15 and an A/G mutation at codon 32 ( Figure 5 ). The coincidence rate for K-ras mutations between stool samples and cancer tissues of CRC patients revealed by chip-based TGCE reached 97% (29/30). Only patient no. 18 showed a positive stool result but a negative tissue result. The coincidence rate obtained by direct sequencing (26/30, 87%) was a little lower, whereas no significant difference was observed.
Reproducibility
Four continuous and separate chip-based TGCE detections of PCR products of stool sample of patient no. 9 were performed to demonstrate the assay variations. The recordings showed in Figure 6 demonstrated good intra-and inter-assay variations in peak migration times and peak patterns. The intra-and inter-assay relative standard deviation (RSD) values of migration times were 1.1% (n ¼ 4) and 3.5% (n ¼ 4), respectively. The peak migration time indicates the time for the charged particles to perform directional motion with the action of electric field, which is one of the important parameters for evaluating the reproducibility of electrophoresis. Chip-based detection of stool K-ras mutation H Zhang et al
DISCUSSION
In the past decade, treatment for CRC has significantly improved with the approval of several novel molecular targeting agents, while certain problems are becoming increasingly evident because patients acquire resistance to targeted therapy. It has been reported that mutant K-ras provides an -, not analyzed.
The symbols (+) and (À) indicate mutant and wild-type K-ras detected by chip-based TGCE.
Chip-based detection of stool K-ras mutation H Zhang et al independent negative predictive marker for EGFR-targeted therapy in CRC; thus, several methods have been established to screen K-ras gene to achieve successful personalized medicine. [4] [5] [6] Based on the good clinical compliance and the findings of several research groups that revealed K-ras mutations in stools consistent with the K-ras status in matching n Two aliquots of the stool sample of patient no. 18 were detected individually.
nn Three parts of the cancer tissues of patient no. 18 were detected individually.
Chip-based detection of stool K-ras mutation H Zhang et al tumor tissues, [28] [29] [30] mutated DNA in stools has become the latest target of several detection methods. [8] [9] [10] Although stoolbased DNA detection could report CRC tissue K-ras genotypes faithfully, severe difficulties because of complicated procedures and low sensitivity have hampered further progress in using stool samples to detect K-ras mutations and preventatively screen for CRC.
In this work, highly sensitive and rapid detection of K-ras mutation was achieved using chip-based TGCE. This assay could reliably detect as low as 0.2% mutant K-ras in a background of wild-type genomic DNA and trace PCR product amplified from 0.5 ng of template, suggesting that this method is capable of detecting low-abundance K-ras mutations in stool samples. The results were much better than those obtained by Li et al, 31 who adopted standard TGCE to detect a model mutant DNA sample diluted with the corresponding wild-type fragment at a ratio of 1:9. As reported by Bian et al, 20 although limiting-dilution PCR (LD-PCR) followed by TGCE significantly improved the detection of detectable mutations to 1%, the remarkably increased numbers of PCR reactions made this work highly uneconomical and time consuming. Mutant allele-specific amplification and mutant-enriched PCR could achieve a very high sensitivity (0.01%). 32, 33 However, the former lacks enough specificity when used to detect gene mutations because the amplification of wild-type will proceed if there is a slight change in conditions; the latter has certain disadvantages of taking time for several consecutive amplifications and introducing mutations during these PCRs. 13, 34 Digital melt curve (DMC), a newly developed screening method, showed a satisfactory scanning ability for low-abundance mutations (0.1%) in the informative regions of target genes, 12 whereas it was expensive at present for use in clinical molecular diagnostic purposes. Time-cost was another important aspect to evaluate the screening method. In the conventional slab gel electrophoresis, several separate steps including gel preparation, sample loading, separation, staining, and photographic imaging will take42 h, whereas on the microfluidic platform all the steps mentioned above can be integrated together to perform on-line detection, resulting in the increased speed. In this study, the whole automated chip electrophoresis could be accomplished within 6 min.
In this study, the K-ras status from 30 paired stool samples and cancer tissues was detectable using chip-based TGCE, and the lowest percentage of the mutant K-ras was 2% in the stool sample of patient no. 14. The detection rate of K-ras mutation in stool specimens from the CRC patients was 57%, which was slightly higher than that noticed in cancer tissues (53%). Currently, the majority of studies have shown that mutations are found more frequently in tissues than in stools. 13, 29, 30, 35, 36 In this study, four patients (nos. 2, 17, 20, and 26) exhibiting mutant electrophoresis patterns in both stool samples and cancer tissues were found by direct sequencing to carry K-ras mutations in their cancer tissues but not in their stool samples, whereas clone sequencing confirmed the K-ras mutations in their stool samples, showing that the proportions of mutant K-ras were 9, 12, 15, and 13%, respectively, which demonstrated the lower abundance of K-ras mutations in stool samples compared with that in cancer tissues. As described in many papers, methods with high sensitivities could achieve high mutation detection rates. 12, 32, 33, 37 Marchetti et al 37 compared direct sequencing with mutation-enriched sequencing in 90 colorectal carcinomas. The prevalence of tumors harboring K-ras mutations was 40% using direct sequencing and 55% using mutationenriched sequencing, which had a higher sensitivity. 37 In our study, K-ras mutations were identified in 57% of the 30 stool samples by chip-based TGCE, significantly higher than that obtained by direct sequencing. Thus, the high stool-based mutation detection rate can be attributable to the high sensitivity of the technique. Simultaneously, with the increase of sensitivity, the coincidence rate for K-ras mutations between stool samples and cancer tissues was also improved. An up to 97% agreement of K-ras mutations was observed between stool samples and cancer tissues from our chip-based TGCE method, which demonstrated that stool DNA-based assays could provide accurate information about CRC patients by using more sensitive methods. In this study, only patient no. 18 presented a positive stool result but a negative tissue result for the K-ras mutation. To further confirm the results, K-ras mutations in two more areas of the cancer tissue and in another aliquot of the stool sample of patient no. 18 were analyzed by chip-based TGCE and confirmed by clone Chip-based detection of stool K-ras mutation H Zhang et al sequencing. As shown in Figure 5 , no mutation was revealed in the cancer tissues, but the stool sample still harbored mutant K-ras. This discordance was probably because of heterogeneity within the same tumor and contaminations of diet or intestinal flora and other gastrointestinal tumors or nonneoplastic conditions such as pancreatic hyperplasia. [38] [39] [40] [41] The protocols of the QIAamp DNA Stool mini kit used here had reduced the ratio of nonhuman DNA as far as possible. In this study, only one healthy volunteer was found to contain K-ras mutations by chip-based TGCE. No significant difference was shown in the specificity of chip-based method and direct sequencing, which indicated that the increased sensitivity did not affect the specificity. Compared with conventional TGCE, the higher sensitivity of the chip-based TGCE method can be attributed to several factors. First, TGCE relies on the electrophoretic separation of homoduplexes and heteroduplexes in the sieving matrix under a given electric field. The high separation efficiency can be obtained by applying high field strength; however, high field strength may produce high joule heating in conventional CE because of a lower ratio of channel surface area to channel volume, resulting in the reduction of separation efficiency. In contrast, if the ratio of surface area to the volume of the channel of the chip-based CE is higher, joule heating is released easily, and higher field can be used to achieve improved resolution, which in turn leads to an excellent separation of homoduplexes and heteroduplexes in TGCE. 42, 43 Second, according to the separation principle of TGCE, the resolution efficiency for mutant DNA fragments is dependent on the temperature melting profile of the detected sequences. If the mutant sequence is located in the lowmelting domain in a whole DNA fragment, the migration differences between heteroduplexes and homoduplexes during CE are readily produced and retained. The mutant codons 12 and 13 are in the relatively high-melting domain in the 253-bp fragments of the K-ras gene, and a GC-clamp is introduced to the fragment to form a high-melting domain relative to mutant base sites. It has been reported that TGCE combined with the GC-clamp technique is capable of achieving nearly 100% mutation detection efficiency. 18 Without the GC-clamp, the 'nonclamped' 253-bp fragments differing by a base change at codon 12 or 13 will not be separated due to the loss of sequence-dependent migration because of complete strand separation. Third, the sensitivity of TGCE is in large part determined by the temperature profile. In this study, an established slantwise radiative heating system is used to produce a stable and uniform spatial temperature gradient along the separation channel by simply slanting a thermostated aluminum heating plate on the chip surface using a thin spacer at the inlet of the separation channel, with a precision of 0.1 1C. 24 The novel property of the heating system ensures good CE separation efficiency and reproducibility. In this study the migration time precisions for the intra-and inter-assay reached 1.1 and 3.5% RSD. Finally, the sensitive LIF detector is applied combined with a new type of fluorescent dye, YOYO-1. YOYO-1 is essentially nonfluorescent in the absence of nucleic acids and exhibits a 100-to 1000-fold increase in fluorescence upon binding to DNA; therefore, this system can detect as low as 0.5 ng/ml of double-stranded DNA (dsDNA). 44, 45 In contrast, the fluorescence of the commonly used EtBr is only enhanced B20-to 30-fold after intercalation into dsDNA, which requires a relatively high concentration of DNA sample to be effective in the TGCE assay (50-500 ng/ml). Meanwhile, unconjugated EtBr itself will cause a high-fluorescence background and interferes with the detection sensitivity. 23, 44, 45 Although our preliminary clinical investigation is limited because of restricted access to more CRC samples, the results of our study showed that the detection accuracy rate reached 100% after verification by clone sequencing. The high accuracy might be due to the relatively high sensitivity of this method, because the mutations harbored in stools can be as little as 1% in general, 11 which is much higher than the threshold concentration (0.2%) of this chip-based TGCE method. From our results, K-ras mutations and base substitutions in stool samples were identical to that in cancer tissues. One of the most significant advantages of TGCE was the ability to detect virtually any base alteration within a gene sequence. In this study, this advantage meant that it could detect mutations at both codons 12 and 13, which were proved to be predictors guiding EGFR-targeted therapy. In this study we observed this phenomenon that mutations at codons 12 and 13 in different samples and within the same sample (cancer tissue of patient no. 21) were both revealed, exhibiting a wide applicability of this assay. Meanwhile, mutations outside codons 12 and 13 could be also revealed according to the basic principle of TGCE, 16 such as a G/A mutation at codon 10 in the stool sample and cancer tissue of patient no. 21 , and a C/T mutation at codon 15 and an A/G mutation at codon 32 in the stool sample of Control-4. Although these mutations were disclosed, the specificity of chip-based TGCE was still up to 93%. As a screening method, the results still should be further confirmed by subsequent sequencing of the gene.
A cost analysis of this process is also critical for chip-based TGCE to become a mutation detection technique, involving chip fabrication and reagents to perform the analysis. In this work, each glass chip costs B2.0 USD, and the cost can be drastically reduced by using polymer materials to perform batch fabrication in the future, matching the requirements for clinical practice such as low-cost, disposability, and individualized detection. An extremely low sample consumption of 14 nl for each analysis was obtained. Furthermore, reagent costs for chip-based TGCE analysis were also quite low because of microscaling, even if the fluorescent dye YOYO-1 was applied. For just the chip-based TGCE portion of the assay, the reagent cost per sample is B0.02 USD.
In conclusion, we developed a highly sensitive and fast chip-based TGCE method for detecting low-abundant gene mutations. The applicability of the method was demonstrated by the successful noninvasive detection of K-ras mutation within stool samples of the CRC patients, which facilitated the therapeutic evaluation of mutations for further personalized therapy. In view of its technological superiority, the chip-based TGCE method exhibits a high potential for more comprehensive application. A large number of different DNA fragments can be detected by TGCE as long as the electrophoresis is performed under an enough wide temperature gradient range to cover their Tm values. In this study the chip-based TGCE platform has been proven to establish a stable and uniform 10 1C temperature gradient and achieve mutation detections of various DNA fragments. 24 Therefore, a panel of target genes associated with specific cancers, including some large genes with widely dispersed potential mutational sites, can be analyzed simultaneously by further developing continuous sample introduction system or increasing the number of parallel channels on the platform, so that the high-throughput detection can be realized. 
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